Coinbase CEO’s Biotech Firm Gets $130M to Fight Aging With AI, Genomics
NewLimit’s Series B raise adds fuel to Silicon Valley’s growing obsession with anti-aging science and biohacking immortality.
Archive context
Older archive item. Useful for background and entity history, but not a fresh market-moving signal.
Why this matters
This cryptocurrency story adds another data point to the current market tape and is useful when read alongside nearby source coverage.
Original source
Read on DecryptRelated market context
Coinbase Adds IPO Shares to Its Expanding Everything Exchange
Coinbase is giving eligible U.S. retail investors access to IPO allocations through its app, beginning with Oura’s offering. The e...
XRP Price Prediction: XRP Could Flip Ethereum as It Targets $3,000
XRP price trades at $1.44, up 4% over the past 24 hours, and the prediction about it eventually flipping Ethereum’s market cap is...
Perplexity AI Predicts Weak XRP Price by 2027: Bull Run Canceled?
The Silicon Valley-based Perplexity AI predicts XRP could have a tame Q4, saying it believes the token will only hit $3.25 by Janu...
Crypto Biz: CLARITY Act setback puts Coinbase in the spotlight
Coinbase draws scrutiny after the CLARITY Act stalls, while the SEC moves ahead with tokenized stocks and crypto firms push deeper...
FCA Targets Three London Premises In Illegal P2P Crypto Trading Crackdown
TL;DR The FCA, HMRC and Metropolitan Police inspected three London premises over suspected illegal crypto trading. Cease-and-desis...
dtcpay Completes $25M Series A As SBI Group Joins Stablecoin Payments Push
TL;DR Singapore payments company dtcpay has completed a $25 million Series A. Vertex Ventures led the original round, with SBI Gro...